Theradiag, Croissy-Beaubourg and Montpellier, France, has launched the Stelara ustekinumab monitoring test in the US market, as part of its partnership with Miraca Life Sciences, Irving, Texas.

Theradiag’s Stelara monitoring kit expands Miraca Life Sciences’ InformTx service in the US market, allowing monitoring of biotherapies for the treatment of inflammatory bowel disease.

“Increasing the number of drugs that we can test with our InformTx therapeutic drug monitoring allows us to provide critical information to help guide therapy for even more gastroenterologists and their patients,” says Richard Lash, MD, chief medical officer and executive vice president of operations for Miraca Life Sciences. “We plan to add more biologics to our InformTx testing service over time.”

InformTx  now features five Theradiag monitoring tests. Miraca Life Sciences started marketing and promoting the service in June 2016, initially with four tests: Cimzia (certolizumab), Entyvio (vedolizumab), Humira (adalimumab), and Remicade (infliximab).

Michel Finance, Theradiag.

Michel Finance, Theradiag.

“Miraca Life Sciences’ US launch of our fifth monitoring test will broaden our offering in the US market, where twice as many patients are treated with biotherapies as in Europe, giving us major sales potential in the next few years,” says Michel Finance, CEO of Theradiag. “Our ambition is to develop monitoring kits for all biotherapies on the market, both current and future, in our key therapeutic areas of expertise—ie, autoimmune and inflammatory diseases—and also to offer them in the US market.”

For more information, visit Theradiag.